Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.
To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.
Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.
|Sponsor Type||Funding Program Title||Amount and Duration||Description||Deadline|
|Tri-Agency||CIHR Team Grant: Pan-Canadian Clinical Trials Consortium||Up to $13M per year for up to 3 years||The purpose of this funding opportunity is to support the creation of a pan-Canadian Clinical Trials Consortium that will strengthen coordination of clinical trials conducted in Canada, as well as Canadian participation in international clinical trials. Up to 1/3 of the total grant is to be used to support new clinical trial networks and their activities||Letter of Intent (LOI): May 25, 2022. LOIs will not be evaluated by a peer review process, only by a relevance review process.
Application (by invitation): July 19, 2022.
|Tri-Agency||CIHR Pre-Announcement: Mental Health in the Early Years (MHITEY) Implementation Science Team Grants||Up to $250,000 per year for up to 5 years.||The goal is to fund implementation science research that enhances our understanding of how to improve the systematic and equitable implementation of evidence-based interventions for young children (i.e., girls, boys and gender diverse children ages 0-5) and their caregivers||Anticipated Timelines:*
Launch: March 2022
Application Deadline: June 2022
*These timelines are estimates and subject to change
|Tri-Agency||Pre-Announcement: CIHR-JDRF Team Grants: Precision Medicine in Type 1 Diabetes (T1D; Anticipatory)||Up to $875,000 per year for up to 4 years, for a total of $3,500,000 per grant.||While this funding opportunity has yet to be finalized, preliminary information at this time is to allow the community to prepare and respond to what will be an expedited process. The objectives of this anticipatory funding opportunity are:|
- To generate knowledge regarding the heterogeneity of T1D that will enable and inform new precision medicine approaches for the prediction, prevention, care or treatment of T1D
- To advance curative and disease-modifying therapies for T1D using precision medicine approaches.
Launch: May 2022
Registration: June 2022
Application Deadline: August 2022
*These dates are estimates and subject to change.
|Tri-Agency||CIHR Pre-Announcement: Policy Research for Health System Transformation||Up to $150,000 per year for 1 year.||This will support grants that generate evidence to inform macro-level policies to support high-performing health care and public health systems in Canada with the aim of advancing the Quadruple Aim - improved population health outcomes, better patient and provider experience, and increased value - and health equity (sometimes referred to as the Quintuple aim).||Anticipated Timelines:*
Launch: May 18, 2022.
Deadline: October 4, 2022.
*These timelines are estimates and subject to change
|Tri-Agency||Pre-Announcement: Operating Grants in Diabetes, Psychosocial Health, Prevention and Self-Management (Anticipatory)||Up to $250,000 per year for up to 4 years, for a total of $1,000,000 per grant.||While this funding opportunity has yet to be finalized, preliminary information at this time is to allow the community to prepare and respond to what will be an expedited process. Specific to T1D, this will support research that is focused on interventions and models of care that address psychosocial issues and mental health disorders in people with T1D and thereby improve mental health and associated quality of life and/or clinical outcomes. Specific to T2D, this will support psychosocial health research focused on prevention and treatment in youth and young adults with a focus on Indigenous and racialized, ethnocultural and low socio-economic status communities that are disproportionately affected by T2D.||Anticipated timeline*
Launch: May 2022
Application Deadline: November 2022
*These dates are estimates and subject to change.
|Tri-Agency||CIHR Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)||Research Grant: Up to $2,000,000 per year for up to 6 years; Collaborating Centre: Up to $350,000 per year for up to 6 years.||This funding opportunity will support projects relevant to the following research areas:|
An I-HeLTI Intervention Cohort Research Study that will encompass the continuum of care and prevention of non-communicable diseases, from preconception to pregnancy, infancy and early childhood with a life trajectory perspective. An I-HeLTI Collaborating Centre that will steward the emerging I-HeLTI cohort, governance processes and data management. Eligibility to apply to this funding opportunity is limited to the three CIHR-funded I-HeLTI research teams.
|June 6, 2022.|
|Tri-Agency||CIHR Pre-announcement: Transforming Health with Integrated Care (THINC) - Implementation Science Teams Grants||Up to $400,000 per year for up to 5 years.||The THINC Implementation Science Team Grants will support interdisciplinary research teams dedicated to understanding the implementation, evaluation, adaptation, and/or and spread/scale of transformative evidence-informed integrated care policies and interventions that will advance the Quadruple Aim and health equity.||Anticipated Timelines*
CIHR Webinar: June 17, 2022 at 2-3:30 pm EST
Deadline: November 1, 2022
*These timelines are estimates and subject to change.
|Tri-Agency||SSHRC Partnership Engage Grants||Between $7,000 and $25,000.||These grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector.||June 15, 2022; September 15, 2022 and December 15, 2022.|
|Tri-Agency||CIHR Team Grant: Mental Health in the Early Years (MHITEY) Implementation Science||Up to $250,000 per year for up to 5 years.||The goal is to fund implementation science research that enhances our understanding of how to improve the systematic and equitable implementation of evidence-based interventions for young children (i.e., girls, boys and gender diverse children ages 0-5) and their caregivers that address one or more of the following areas:|
- Promotion of positive socio-emotional development and mental health in early childhood;
- Prevention of the development of early childhood mental health issues; and
- Treatment of young children living with or at risk of developing mental health issues through integrated, coordinated and person-oriented care.
|June 23, 2022.|
|Tri-Agency||CIHR Operating Grant: Psilocybin-assisted Psychotherapy||Up to $500,000 per year for up to 2 years.||This funding opportunity will support phase 1 or 2 randomized clinical trials relevant to psilocybin-assisted psychotherapy in the treatment of the following research areas:|
- Substance use dependence or substance use disorders
- Major Depressive Disorder (MDD) or treatment resistant depression
- End-of-life psychological distress in patients with advanced-stage cancer
|Registration: September 6, 2022.
Application: October 4, 2022.
|Tri-Agency||Tri-Council Special Response Fund for Trainees Ukraine (SRFT-Ukraine)||Master's level: Up to $20,000; Doctoral level: Up to $25,000; Postdoctoral level: Up to $45,000. Support can be requested for a period of up to 12 months. Requested amounts will be pro-rated to reflect the expected duration of the support.||This limited-time fund is to initiate or maintain the employment or financial support of trainees who are directly impacted by the crisis in Ukraine. CIHR- NSERC- and SSHRC-funded grant holders can apply. This additional funding for grant holders will support trainees, defined as graduate students or postdoctoral researchers through salaries and stipends.||Continuous intake until December 22, 2022.|
|Tri-Agency||CIHR Pre-Announcement: Clinical Trials Fund (CTF)||--||CIHR will provide grants to support an array of clinical trial phases, designs, and objectives across a broad range of health research areas, aligning with the priorities of the Biomanufacturing and Life Sciences Strategy, including the development and testing of new drugs, treatments, and public health and health system interventions to prevent, detect, treat, or manage various diseases or medical conditions. The CTF will provide funding through 3 specific vehicles: platforms with the development of a pan-Canadian Clinical Trials Consortium; people with the funding of training platforms; and, projects through the funding of a broad spectrum of clinical trial initiatives.||Anticipated Timelines*:
Launch: Spring 2022
Deadlines: Summer 2022
*Estimates and subject to change
|Tri-Agency||NSERC Alliance/Mitacs Accelerate Grants||--||This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.||Ongoing|
|Tri-Agency||NSERC Alliance Grants||$20,000 to $1 million per year for 1-5 years||Support university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.|
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Tri-Agency||NSERC Alliance International||- Catalyst Grants: These will allow Canadian researchers to identify and initiate the first stage of collaboration. Value: $25,000 for 1 year.|
- Collaboration Grants: These will allow Canadian researchers to participate in internation
|These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application. |
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
|Other Canadian||Canada Biomedical Research Fund (CBRF) Stage 1: Research Hubs Selection||$500,000 per year for up to 4 years.||This will support research hub applications aligned with Canada's Biomanufacturing and Life Sciences Strategy and proposing demonstrable contributions toward pandemic preparedness and the following goals: |
- Increase specialized infrastructure, and capacity for multidisciplinary, applied research.
- Support training and development, to expand the pipeline of skilled research and talent.
- Accelerate the translation of promising research into commercially viable products and processes.
The aim is to improve pandemic readiness and sector growth by strengthening research and talent capacity in Canada, and contributing to and leveraging collaborations across the entire biomanufacturing ecosystem and various sectors. The focus is pathogens with the greatest pandemic potential, especially respiratory and zoonotic diseases.
|Notice of Intent: May 19, 2022.
Deadline: July 21, 2022.
|Other Canadian||Canadian Cancer Society (CCS) Accelerator Grants||Synthesis Grant: Up to $50,000 per year for 1-2 years; Implementation Science Grant: Up to $100,000 per year for 1-2 years.||This funding opportunity is intended to stimulate the implementation of evidence-based programs, practices, and policies (i.e. interventions), within 2-5 years, that will improve the lives of people affected by cancer. Synthesis grants can be used to determine the effectiveness of existing clinical or other interventions. Implementation science grants may not be used to develop, adapt, or test the effectiveness of clinical or other interventions themselves.||Registration: May 25, 2022.
Full Application (by invitation): July 20, 2022.
|Other Canadian||Global Alliance for Chronic Diseases (GACD) 7th Call for Applications||For CIHR, up to CAD $400,000 per year for up to 5 years.||This focuses on implementation research to reduce the non-communicable disease burden by targeting critical life stages and key transitions between life stages. Research should aim to improve health equity in low- and middle-income countries or among disadvantaged populations in high-income countries. While not yet available, applicants will be directed to view the call text on CIHR's ResearchNet website for complete information regarding CIHR-specific research areas of interest.||May 31, 2022.|
|Other Canadian||St. Joseph's Health Centre (SJHC) Research Seed Grant Competition||--||This annual funding opportunity supports research led by SJHC researchers and conducted at SJHC or its catchment area. Adjudication is based on: 1) innovation and alignment, 2) approach / methodology, 3) team, and 4) impact. Application can be requested through VPRI@smh.ca.||All applications are due June 1, 2022.|
|Other Canadian||University of Toronto Early Stage Technology Program (UTEST) Applications||Investment funding of up to $150,000, 12 months of incubation space, intense entrepreneurial education provided by MaRS, corporate and intellectual property legal support, mentoring and business strategy support.||Applications are open to companies with one or more founders affiliated with U of T. Since 2020 UTEST has accepted applications from U of T-affiliated hospitals. Please ensure an invention disclosure form has been submitted to your host institutions technology transfer office and they are aware of your UTEST application.||June 2, 2022.|
|Other Canadian||The Manchester-Melbourne-Toronto (MMT) Research Fund||Up to ~$22,000 for bilateral or up to ~$33,000 for trilateral for 18 months.||This supports proposals that will lead to long-term research collaborations with a view to enabling principal investigators to subsequently apply for external funding to support the next phase of their joint research. It is open to applications from all research areas. Projects must include research team participants from a minimum of two of the three institutions and must be led by, or include in a significant role, Early Career Researchers. U of T applicants must hold a continuing faculty appointment.||June 16, 2022.|
|Other Canadian||Brain Tumour Foundation of Canada (BTFC) Research Grants||Up to $25,000 for up to 2 years.||BTFC seeks outstanding researchers conducting quality brain tumour research. All such proposals will be given consideration. Additionally, we are interested in receiving innovative research proposals which incorporate novel or original concepts that have the potential to make a difference and projects that involve collaboration. Adult and pediatric brain tumour projects in basic, clinical or translational research will be considered.||June 17, 2022.|
|Other Canadian||Gairdner Ontario Programs Call For Proposals 2022||Range from $5,000 - $25,000 per event.||This will fund events that promote excellence and involvement in science in the province of Ontario. Events should are unique, free or low cost to attend, and represent the Gairdner dedication to excellence in research in the fields of human biology and medicine. This program is not intended to support annual meetings, administrative costs or as a research grant of any kind. Submissions must be submitted at least 6 weeks in advance for most events, and at least 8 weeks for a symposium level event.||October 1, 2022.|
|Other Canadian||Mitacs Accelerate: Eligibility and New Program Updates||--||Options and enhancements include expanding eligibility for both interns and external sponsoring partners, and increasing support levels for some partners.|
Mitacs Accelerate-Expanded Eligibility Criteria: Mitacs can now support undergraduate students as interns on a Mitacs Accelerate grant. In addition, municipalities and hospitals are now considered to be eligible partner organizations for Mitacs Accelerate
Mitacs SME Discount Model:Until February 1, 2022, a partner organization that is a small/medium-sized enterprise (SME) in the for-profit or non-profit sector will only be charged 25% of the overall project costs instead of Mitacs's typical 50% cost-sharing ratio. Details here: Link.
Accelerate Industrial Post-Doctoral Fellowship-New Funding Model: This funding stream provides $60,000/year for a post-doctoral fellow, where the partner organization must contribute $30,000 plus applicable taxes per year. Details here: Link.
Mitacs and National Research Council (NRC) collaborative funding stream for R&D projects: Support for 250 graduate and post-graduate student internships within the NRC's Challenge and Supercluster support programs. Details here: Link.
|Other Canadian||New Mitacs Initiatives and Opportunities||--||Mitacs Parterships with Municipalities: Professors, postdoctoral fellows, graduate students, college students and undergraduate students can now put their talent to work on a collaborative research project at a municipality that needs your expertise. Canadian municipalities of all sizes are now eligible partners for co-funded projects involving post-secondary researchers through Mitacs programs. Details here: Link.|
Mitacs Partnerships with Hospitals: This initiative empowers Canadian hospitals no matter the size, by providing access to the brightest post-secondary researchers and funding for innovative projects. Whether you are a hospital administrator looking to collaborate with experts across a myriad of disciplines or an academic whose research could benefit a hospital, Mitacs can help. Details here: Link.
Indigenous Pathways Initiative: Projects are a minimum of four months in duration - they can be longer - and now Indigenous-owned businesses and organizations contribution is only 25% of the cost of projects that have an Indigenous partner organization and/or an intern who is Indigenous. Details here: Link.
|Other Canadian||University of Toronto Institutional Strategic Initiatives (ISI)||From $50,000-$300,000 per year for up to 3 years.||ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding.||Ongoing|
|Other Canadian||Collaboration Opportunities: National Research Council Canada (NRC) Challenge Programs||--||The NRC offers potential opportunities for collaboration in the following areas:|
- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response
Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
|Other Canadian||Government of Canada: CanExport for Innovators||Maximum of $75,000||Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.|
Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
|Other Canadian||Weston Brain Institute: Early Phase Clinical Trials: Canada||Up to $1,500,000 per project for up to 4 years||Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.||Rolling deadline
|Other Canadian||Physicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator Grant||Health Research Grant: Up to $250,000 for 3 years.|
New Investigator Grant: Up to $300,000 for 3 years.
|Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment.||Rolling deadline|
|Other Canadian||Telus Funds||Various||For entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.||Various
|Other Canadian||Ontario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program||Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)||This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).|
If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to ).
|International||Lung Cancer Research Foundation (LCRF): Various Opportunities||Check individual funding opportunities.||LCRF Minority Career Development Award (CDA) in Lung Cancer: for minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees. For full details, eligibility criteria, and application instructions, please refer to the request for proposals. Value: USD $150,000 for a period of 2 years.||LCRF Minority Career Development Award (CDA) in Lung Cancer -May 27, 2022.|
|International||International Center for Responsible Gaming (ICRG) 2022 Grants Program||Large Grants: Up to USD $75,000 per year for up to 24 months.||These grants are to explore the etiology, prevention and treatment of gambling disorder, and the development and evaluation of responsible gambling strategies.||Large Grants: June 30, 2022.|
|International||American Society of Hematology (ASH) Bridge Grant Program||USD $150,000 for 1 year.||These are granted to ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients' research and contribute to their retention in hematology investigation while they reapply.||November 1, 2022.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Lung Cancer Research Program (LCRP)||Check individual funding opportunity.||Clinical Translational Research Partnership Award: Supports translational studies that include an interventional clinical trial. Value: Up to USD $1.2 million for up to 3 years.||Clinical Translational Research Partnership Award - Pre-Application: July 13, 2022; Application: July 27, 2022.
|International||Embassy of the United States of America - Canada (U.S. Mission in Canada) Public Affairs Section (PAS): Combatting COVID-19 Grant Program||Between USD $15,000-$100,000 for up to 24 months.||This invites proposals that that strengthen the bilateral ties between the U.S. and Canada and support the Roadmap for a Renewed U.S.-Canada Partnership Pillar Combatting COVID-19, including, but not |
- Programs and initiatives to combatting mis- and dis-information around COVID-19 and vaccinations and promote the importance of science-based public health measures in response to the pandemic.
- Messaging, information, and educational programs and campaigns that engage youth and underserved communities, and that address information and other disparities between communities and rural and urban audiences.
|July 6, 2022.|
|International||Cystic Fibrosis Foundation (CFF): Various Opportunities||Check individual funding opportunities.||Pilot and Feasibility Award: Supports (non-Path to a Cure related) basic science research studies focused on developing and testing new hypotheses in areas relevant to cystic fibrosis. Value: Up to USD $50,000 per year for up to 2 years.|
Path to a Cure Pilot and Feasibility Award: Supports basic science research studies focused on developing and testing new hypotheses in areas relevant to the Path to a Cure Initiative (see guidelines for areas of interest). Value: Up to USD $50,000 per year for up to 2 years.
Research Grants: Support basic science research. Studies may be carried out at the subcellular, cellular, animal, or patient levels. Value: Up to USD $150,000 per year for up to 2 years.
Path to a Cure Research Grants: Should focus on foundational concepts, strategies, novel tools and methods, and/or technologies that have the potential to inform or ultimately translate into novel therapies to restore CFTR protein function or fix/replace the defective CFTR gene. Value: Up to USD $50,000 per year for up to 2 years.
CFF/NIH R01-Unfunded Award: This supports excellent cystic fibrosis-related research projects that have been approved by the National Institutes of Health (or governmental funding agencies in other countries) but cannot be supported by available funds. Value: Up to USD $125,000 per year for up to 2 years.
Path to a Cure - Pioneer Award: For ambitious basic research projects aiming to utilize cutting-edge techniques and strategies that have the potential to discover new genetic-based therapies for cystic fibrosis.
Path to a Cure Research Grants :May 19, 2022.
CFF/NIH R01-Unfunded Award : December 15, 2022.
Path to a Cure - Pioneer Award :Rolling.
|International||Biogen: Various Opportunities||--||Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas: |
Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Patient Education: Supports independent educational activities for patients or caregivers.
General Grant: Supports a project or program that does not fit any of the other defined grant categories.
|August 15, November 1.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Peer Reviewed Epilepsy Research Program (ERP)||Idea Development Award: Funding Level 1: Up to USD $300,000 for up to 3 years; Funding Level 2: Up to USD $550,000 for up to 3 years.|
Research Partnership Award: Up to USD $1.3M total costs for up to 3 years.
Virtual Post-Traumatic Epilepsy Research Center (P-TERC): Up to USD $1.25M for up to 4 years. Faculty Award: Focuses on the PIs research and career development. Value: Up to USD $500,000 for up to 3 years.
|This is anticipated to provide funding for the ERP to understand the mechanisms of post-traumatic epilepsy (PTE).|
Idea Development Award: Supports novel, innovative research to understand the magnitude and underlying mechanisms of PTE. Value: Funding Level 1: Up to USD $300,000 for up to 3 years; Funding Level 2: Up to USD $550,000 for up to 3 years.
Research Partnership Award: To create an avenue for synergistic, collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. Value: Up to USD $1.3M total costs for up to 3 years.
Virtual Post-Traumatic Epilepsy Research Center (P-TERC): Leadership Award: Applicants will act as the Director and Deputy Director to lead the center in meeting its overarching goal. Value: Up to USD $1.25M for up to 4 years. Faculty Award: Focuses on the PIs research and career development. Value: Up to USD $500,000 for up to 3 years.
|Pre-Application: May 19, 2022.
Application: June 23, 2022.
|International||United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP) FY 2022 Spinal Cord Injury Research Program (SCIRP): Various Opportunities||Check individual funding opportunity.||- Clinical Trial Award: Funds Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of SCI and its consequences. Value: Up to USD $3M for up to 4 years; Early-Career Partnering PI Option up to USD $3.1M for||Pre-Application: May 23, 2022.
Application (by invitation): September 2, 2022.
Chan Zuckerberg Initiative: Patient-Partnered Collaborations for Rare Neurodegenerative Disease
|USD $500,000 total costs per year for up to 4 years.||This invites applications from collaborative teams bringing together patient-led rare disease organizations and research teams research projects aimed at advancing our understanding of the of the pathophysiology and mechanistic underpinnings of rare neurodegenerative and neurological disorders.||May 24, 2022.|
Society for the Advancement of Blood Management (SABM) Research Grant
|USD $25,000 for 1 year.||This grant provides starter funding to further scientific inquiry and clinical knowledge in the field of patient blood management. Applications are open to fellows and junior faculty (five years or less out of training and at a rank no higher than Assistant Professor). Applications are also open to nurses, pharmacists, perfusionists, and blood management or bloodless program coordinators. It is expected that all applicants will be members of SABM, or will become members of SABM for at least one year.||June 1, 2022.|
|International||US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Kidney Cancer Research Program (KCRP): Various Opportunities||Various||Idea Development Award: Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. Value: Up to USD $675,000 for up to 3 years; Early Detection Option: Up to USD $700,000 for up to 3 years.|
Translational Research Partnership Award: Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer toward clinical applications. Value: Up to USD $750,000 for up to 3 years.
Concept Award: Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Funding for clinical trials not allowed. Value: Up to USD $100,000 for up to 1 year.
Idea Development Award: Pre-Application: June 2, 2022; Application (by invitation): October 6, 2022.
Translational Research Partnership Award:Pre-Application: June 2, 2022; Application (by invitation): October 6, 2022.
Concept Award:: Pre-Application: June 23, 2022; Application: July 14, 2022.
|International||Intuitive Foundation Clinical Research Grants for Robotic-Assisted Surgery||Up to USD $60,000 total costs for up to 2 years.||These grants support clinical research at non-profit institutions worldwide focused on the field of robotic-assisted surgery. Successful proposals will study important questions related to surgical care and patient outcomes. Please see the Clinical Research Grants website for the 2022-2023 areas of interest.||Letter of Intent: June 3, 2022.
Full Application (by invitation): September 9, 2022.
|International||Mendez National Institute of Transplantation Foundation (MNITF) Research Grant Program (RGP)||Up to USD $150,000 for up to 2 years.||These grants support innovative research to advance the science and practice of organ transplantation. The focus of Immediate Impact funding is to benefit the transplant community through improved organ donor screening, organ quality assessment, and predictive indicators. The aim of Visionary Research funding is to provide grant opportunities that focus on longer-term goals with significant potential for future impact.||Letter of Inquiry: June 15, 2022; November 1, 2022.
Application (by invitation): July 31, 2022; December 15, 2022.
|International||ResMed Foundation: Physician and Public Awareness||USD $10,000.||This is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. Only programs that have wide outreach to a significant clinical or public population base will be considered.||June 15, 2022; December 15, 2022.|
|International||FY22 Peer Reviewed Orthopaedic Research Program (PRORP): Various Opportunities||Check individual funding opportunities.||Applied Research Award: Supports applied research applications focused on advancing optimaltreatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work. Value: Up to USD $725,000 for up to 3 years.|
Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates. Value: Research Level 1: Up to USD $2.5M for up to 4 years; Research Level 2: Up to $3.0M for up to 4 years.
Clinical Translational Research Award: Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial. Value: Up to USD $1.5M for up to 4 years.
Pre-Application: June 16, 2022.
Application: September 13, 2022.
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Rare Cancers Research Program (RCRP)||Check individual funding opportunity.||CDMRP will follow the definition of rare cancer as an incidence of six or fewer cases per 100,000 people per year in the US.|
Idea Development Award: Preliminary data with disease-specific rationale to support the feasibility of the research hypotheses and research approaches are required. Focus Areas: Biology and Etiology; Research Model; Therapy. Value: Up to USD $350,000 for up to 3 years.
Resource and Community Development Award: Supports development of platforms for multiple rare cancers, to allow sharing of data, bio-specimens, and resources. Value: Up to USD $600,000 for up to 3 years.
Concept Award: Supports innovative, high-risk/high-reward research. Proof-of-concept is the anticipated outcome.Must address one or more of the following Focus Areas: Biology and Etiology; Research Model; Therapy. Value: Up to USD $100,000 for up to 1 year
Idea Development Award:Pre-Application: June 22, 2022; Application: September 30, 2022.
Resource and Community Development Award:Pre-Application: June 22, 2022; Application: September 30, 2022.
Concept Award:Pre-Application: July 18, 2022; Application: August 29, 2022.
|International||TreeFrog Therapeutics Stem Cell Spaceshot Grant||USD $100,000 for 12-24 months.||This is a contest is to support bold scientists willing to explore uncharted territories for a research project in the field of stem cell biology. Eligible topics are: 1. Progressing stem cell culture and cell therapy products through biomimetic strategies; 2. Upgrading stem cell-products and manufacturing processes using new technologies and scientific approaches; 3. Improving the quality control and safety profile of stem cells and stem cell-derived transplants; 4. Enhancing the engraftment, integration and long-term survival of stem-cell derived transplants.||June 30, 2022.|
American Psychological Foundation (APF): Various Opportunities
| APF/Division 39 Grant: USD $7,000. |
David H. and Beverly A. Barlow Grant:Up to USD $7,500.
Marian R. Stuart Grant: Up to USD $20,000.
NOTE: The above list includes those grants valued at least USD $5,000. Please see the APF website for other opportunites valued less than USD $5,000.
|APF/Division 39 Grant: Supports efforts in education, research, and service that advance and encourage the field of psychoanalysis. |
Marian R. Stuart Grant:Support to to further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicant must be an early career researcher (no more than 10 years postdoctoral).
|APF/Division 39 Grant: June 30, 2022.
David H. and Beverly A. Barlow Grant:September 15, 2022.
Marian R. Stuart Grant:July 1, 2022.
|International||Paralyzed Veterans of America (PVA) Research Foundation: Various Opportunities||Up to USD $75,000 for 1 year or up to $150,000 for 2 years.||PVA supports innovative research that improves the lives of those with spinal cord injury and disease (SCI/D).|
- Basic Science: Laboratory research in the basic sciences to find a cure for SCI/D.
- Clinical: Clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions to alleviate these effects.
- Design and Development: Of assistive technology for people with SCI/D, which includes improving the identification, selection and utilization of these devices
|July 1, 2022.|
|International||Baxter Investigator Initiated Research (IIR) Grants: Various Opportunities||--|| Advanced Surgery: the focus is on all products within Advanced Surgery that can address challenges faced during surgical procedures; specifically, hepatic, pancreatic, general surgery, lung, bariatric, cardiovascular, microvascular, colorectal,neurologic and spine related procedures. |
Nutrition: the focus is on clinical outcomes, and/or health economic benefits, and/or impact of various nutrition formulations and/or compounding devices.
Medication Delivery: The focus is to contribute to scientific knowledge in topics of monitoring, drug delivery, infusion therapy, IV workflow management, fluid management, or optimizing patient outcome.
Pharmaceuticals: The focus is on Desflurane, injectable IV medications, and CONTRAFluran.
Acute Therapies: The focus is on blood purification including diagnostics/biomarkers, including preliminary prospective studies on the value of biomarkers in sepsis and other multi organ syndromes; ECCOR/PrismaLung+, CRRT, AKI Diagnostics/Nephroclear.
Renal Care: The focus is to augment the knowledge on Baxter Renal Care therapies through high-quality clinical and health-economic research in areas of individualized patient-centered care, time on therapy, patient experience, clinical outcome, and total cost of care.
| Advanced Surgery: July 7, 2022; September 7, 2022.
Nutrition: July 7, 2022; September 7, 2022.
Medication Delivery: July 14, 2022; September 14, 2022.
Pharmaceuticals: July 14, 2022; September 14, 2022.
Acute Therapies: July 14, 2022; September 14, 2022.
Renal Care: July 21, 2022; September 21, 2022.
|International||Pre-Announcement: United States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY 2022 Peer Reviewed Cancer Research Program (PRCRP): Various Opportunities||Check individual funding opportunity.||To be considered for funding, applications for the FY22 PRCRP must address at least one of the FY22 Topic Areas listed on the opportunity website. Research applications in the areas of breast, kidney, lung, prostate, pancreatic, rare cancer, ovarian cancer, or melanoma are prohibited and will not be accepted. The FY21 PRCRP requires all applications to answer at least one of the Military Health Focus Areas listed on the opportunity website.|
- Behavioral Health Science Award: Supports innovative research and high-reward concepts that span the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer. Value: Up to USD $1M for up to 4 years.
- Career Development Award- Fellow Option: Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher. These are independent investigators at or above the level of Assistant Professor or Instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline. Value: Up to USD $400,000 for up to 3 years.
- Career Development Award- Virtual Cancer Center Scholar Option: Supports the addition of new early-career investigators (Scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of independent cancer researchers. These are independent investigators at or above the level of Assistant Professor or Instructor (or equivalent), on tenure track (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline. Value: Up to USD $800,000 for up to 4 years.
- Translational Team Science Award: Emphasizes multi-PI, multidisciplinary collaborations. Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research. Not intended to support high throughput screenings, sequencing, etc. Value: Up to USD $2.5M for up to 4 years.
- Convergent Science Cancer Consortium Development Award: Infrastructure development to establish the necessary collaborations amongst a Coordinating Center and Research Sites. Multi-Institution collaboration required. Minimum of three separate institutes: one Coordinating Center and at least two Research Sites (other than the Coordinating Center). Value: Up to USD $2.5M for up to 2 years.
- Idea Award: Supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research. Emphasis on innovation. Value: Up to USD $400,000 for up to 2 years.
- Impact Award: Supports hypothesis-driven, high impact research. Encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a near term, major impact on one of the FY21 PRCRP Topic Areas. Value: Up to USD $1.0M for up to 3 years.
|Translational Team Science Award:
Pre-Application: July 12, 2022.
Application: August 2, 2022.
Convergent Science Cancer Consortium Development Award:
Pre-Application: July 12, 2022.
Application: August 2, 2022.
Pre-Application: May 25, 2022.
Application: September 7, 2022.
|International||Society for Emergency Medicine (SAEM) Foundation (SAEMF): Various Opportunities||Range from up to USD $4,000 to up to USD $150,000 per year for 1 or 2 years.||These grants to help fund innovative research and education initiatives in the field of emergency medicine. Grants of various size and scope are available. Please see the SAEM Research Grants website for a list of the available grants. |
NOTE: For all grants, the applicant must be a member of SAEM in good standing at application deadline and during the entire award period.
|August 1, 2022.|
|International||Orthopaedic Research Society (ORS)/Orthoregeneration Network (ON) ON/ORS Kick-Starter Grants||USD $10,000.||These grants support research that focuses on an innovative approach in regenerative orthopaedics or that answers an important open question in that field. The topic is innovative techniques and materials for the regeneration of musculoskeletal tissues. Candidates must be ORS members at the time of application and have not benefited from an ON/ORS support program before.||November 1, 2022.|
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Chronic Pain Management Research Program (CPMRP): Various Opportunities||Check individual funding opportunity.||Clinical Exploration Award: Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers. Studies evaluating opioid-based therapeutic interventions are not allowed. Value: Up to USD $250,000 for up to 2 years.|
Investigator-Initiated Research Award: Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life. Clinical trials are not allowed. Value: Up to USD $900,000 for up to 4 years.
Translational Research Award: Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications. Studies evaluating opioid-based therapeutic interventions are not allowed. Value: Up to USD $1.4M for up to 4 years.
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Combat Readiness - Medical Research Program (CRRP) Rapid Development and Translational Research Award (RDTRA)||RDTRA: Up to USD $2.2M total costs for up to 2 years; RDTRA with Option: Up to USD $2.2M total costs for up to 2 years + Option of $1.0M total costs for up to 1 year.||This support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service Members in current and future battlefield settings. Applications must address one or more of the following Focus Areas: Solutions to enhance Warfighter readiness; Solutions to enhance combat care delivery throughout the far-forward environment; Wound-care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care.||TBA.|
|International||Pre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Multiple Sclerosis Research Program (MSRP)||Check individual funding opportunity.||The CDMRP has pre-announced the following FY 2022 opportunities. Please see details of these at the MSRP link.|
- Clinical Trial Award: Funding Level 1 supports early-phase, proof-of-principle clinical trials to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this Funding Level. Value: Up to USD $1.6M total costs for up to 3 years. Funding Level 2 supports larger-scale clinical trials at phase 1 or 2 that seek to show preliminary evidence of safety or efficacy (benefit on clinical or paraclinical outcomes) in relevant patient populations. Value: Up to USD $4.5M total costs for up to 4 years.
- Early Investigator Research Award: The applicant must be involved in a postdoctoral training or medical residency program and possess at least 1 and up to 4 years continuous postdoctoral research experience; and commit at least 50% of their effort towards project. Value: Up to USD $320,000 total costs for up to 2 years.
- Exploration - Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. Value: Up to USD $250,000 total costs for up to 2 years.
- Investigator-Initiated Research Award: Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care. Clinical trials not allowed. Value: Up to USD $1.0M total costs for up to 3 years.
|International||Alzheimer's Association: International Research Grant Program||--||Multiple Opportunities||Various
|International||Solving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research||$50,000 to $500,000 USD for up to 2 years.||The TDI of SKC only supports clinical research.||Preliminary Proposal Deadline: Ongoing|
|International||Össur Orthopaedic Research Grant Program||--||This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.||Rolling Deadline|
|International||Gateway for Cancer Research (GFCR): Various Opportunities||GFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years|
GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years.
SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years.
|Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine.|
GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world.
GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.
GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps.
|GFCR Grant Program: Rolling Deadline
GFCR Integrative Program:Rolling Deadline
SIO / Gateway Integrative Research Grant Program: Rolling Deadline
|International||Aesculap Implant Systems Investigator-Initiated Study Program (IIS)||--||This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.||Continuous intake|
|International||Bausch + Lomb Grants||--||Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.|
Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers' standard of care, efficacy, patient satisfaction, safety and vision performance.
|Rolling submission. Allow 6-12 weeks for proposal review and decision.|
|NIH||NIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)||--||This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan.||Standard due dates apply until May 8, 2025.|
|NIH||NIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)||--||This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients.||May 26, 2022; September 26, 2022; May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024.|
|NIH||Neural Regulation of Cancer|
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
|--||These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.||May 27, 2022.|
|NIH||NIH Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia (R01 Clinical Trial Not Allowed)||--||This supports research projects focused on development and/or production of medical diagnostics that permit rapid differential species identification, and corresponding phenotypic antibacterial susceptibility profiles for bacteremia or hospital acquired pneumonia. The primary goal of such diagnostics is to facilitate antibacterial stewardship, thereby reducing selective pressure and improving patient outcomes.||June 1, 2022.|
|NIH||NIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)||_||The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target.||June 2, 2022; October 4, 2022; February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024.|
|NIH||NIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)||--||This encourages grant applications that address the influence of patient activation on self-management of chronic conditions.||New Applications: June 5, 2022; February 5, 2023;
AIDS Applications: May 7, 2022; September 7, 2022; May 7, 2023.
|NIH||NIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)||--||This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness.||June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities||--||The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations.||This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse||--||This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes.||This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.|
|NIH||NIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)||--||This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).||June 7, 2022; October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)||--||This supports interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive.||June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023.|
|NIH||NIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.||June 9, 2022; October 11, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.|
|NIH||NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.||June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023.|
|NIH||NIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)||--||The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application.||June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023.|
|NIH||Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)||--||This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2022.|
|NIH||Single-Site Investigator-Initiated Clinical Trials (R61/R33)||--||This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.||June 10, 2022.|
|NIH||NIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)||--||The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.||June 10, 2022; October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.|
|NIH||NIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)||--||This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.||June 14, 2022; June 14, 2023; June 14, 2024.|
|NIH||NIH Informatics Technologies for Cancer Research and Management||--||This invites applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.|
- Development of Innovative Informatics Methods and Algorithms (R21 Clinical Trial Optional):This supports the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research.
-Early-Stage Development (U01 Clinical Trial Optional):For initial tool development or the significant modification of existing tools for new applications.
-Advanced Development (U24 Clinical Trial Optional): For emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.
-Sustained Support (U24 Clinical Trial Optional):This focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources.
|June 14, 2022; November 17, 2022.|
|NIH||NIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities||--||NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.|
PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
|June 15, 2022; October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.|
|NIH||NIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)||--||This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.||June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.|
|NIH||NIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)||--||The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.||June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; October 18, 2024; February 19, 2025.|
|NIH||NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)||--||This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.||June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.|
|NIH||National Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)||--||This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.||June 21, 2022.|
|NIH||NIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities||--||This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. |
- PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products.
- PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
- PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
|June 21, 2022; June 21, 2023; June 21, 2024.|
|NIH||NIH Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)||--||National Institute of Mental Health seeks applications for pilot research to develop and test just-in-time adaptive intervention augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change.||June 22, 2022; February 22, 2023.|
|NIH||NIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)||--||This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies.||Deadlines: June 22, 2022; October 7, 2022; February 8, 2023; June 13, 2023; October 10, 2023; February 8, 2024; June 10, 2024; October 8, 2024; February 10, 2025.|
|NIH||NIH BRAIN Initiative: Targeted BRAIN Circuits Projects||--||R34 Clinical Trials Not Allowed:For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying||R34 Clinical Trials Not Allowed Deadlines: July 1, 2022; October 5, 2022; June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024.
R01 Clinical Trial Not Allowed Deadlines: July 1, 2022; October 6, 2022; June 30, 2023; October 4, 2023; June 28
|NIH||NIH HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes and Cells (U19 Clinical Trial Not Allowed)||--||Supports research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing.||July 7, 2022; October 11, 2022; March 9, 2023.|
|NIH||NIH Research on Current Topics in Alzheimer's Disease and Its Related Dementias||This invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding.|
- - R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field.
- - R01 Clinical Trial Optional
|July 8, 2022; November 14, 2022; March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024.|
|NIH||NIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)||--||This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.||July 14, 2022; September 7, 2022.|
|NIH||NIH Tobacco Regulatory Science (R01 Clinical Trial Optional)||--||This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).||July 14, 2022; February 14, 2023.|
|NIH||Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)||--||The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.||July 19, 2022; November 7, 2022|
|NIH||NIH Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)||--||This supports basic research to define cellular and molecular mechanisms within persistent HIV reservoir cells that promote survival and resistance to virus-induced and immune-mediated cell death, and to identify novel therapeutic targets that could sensitize HIV-infected cells to eradication strategies.||August 3, 2022.|
|NIH||NIH Accelerating the Pace of Drug Abuse Research Using Existing Data||_||This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications.|
R21 Clinical Trial Optional
R01 Clinical Trial Optional
|August 5, 2022; November 15, 2022; March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.|
|NIH||NIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)||--||The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.||August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.|
|NIH||New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service|
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
|--||This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.|
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
|August 11, 2022; November 18, 2022; August 11, 2023|
|NIH||NIH HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)||--||This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.||August 15, 2022; February 15, 2023; August 15, 2023; February 15, 2024.|
|NIH||NIH Urgent Awards: COVID-19 Mental Health Research||--||These aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic.|
- R01 Clinical Trial Optional: Supports 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development.
- R01 Clinical Trial Required: Supports research to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions to respond to new and worsening mental illness and HIV-related outcomes among those who experience COVID-19 as well as the broader population impacted by the pandemic.
|August 25, 2022; December 23, 2022.|
|NIH||Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)||--||The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.||Applications will be accepted on a rolling basis, expiring on September 1, 2022.|
|NIH||Notice of Special Interest (NOSI): Research in the Emergency Setting||--||This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.||This notice applies to receipt dates through September 8, 2022.|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children||--||This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children.||This notice applies to subsequent receipt dates through September 8, 2022.|
|NIH||NIH National Library of Medicine Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)||--||The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects.||Standard dates apply until September 8, 2022.|
|NIH||NIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)||--||The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.||September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.|
|NIH||NIH Social Disconnection and Suicide Risk in Late Life||--||This encourages research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental|
- - R21 Clinical Trial Optional: Most appropriate for high risk/high payoff projects that lack preliminary data.
- - R01 Clinical Trial Optional: For applications with preliminary data.
|October 15, 2022.|
|NIH||NIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research||--||This is for exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. |
R61 Clinical Trial Not Allowed: This is suitable for projects that are at their inception, conceptual, or idea-based phase. In this phase, the technical feasibility of the proposed technology or methodology should not yet have been established.
R33 Clinical Trial Not Allowed: This is suitable for projects that have overcome major feasibility gaps for the technology or methodology as demonstrated with supportive preliminary data but still require further development and rigorous validation to encourage adoption by the research community.
|September 22, 2022.|
|NIH||NIH Dementia Care and Caregiver Support Intervention Research||--||R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.|
R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
|October 11, 2022; February 10, 2023; October 10, 2023; February 13, 2024.|
|NIH||NIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)||--||This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.||November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.|
|NIH||NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)||--||This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH).||PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023.
|NIH||NIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)||--||This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.||This notice applies to subsequent receipt dates through January 7, 2023.|
|NIH||Co-infection and Cancer|
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
|--||The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.||Standard dates apply until January 8, 2023.|
|NIH||Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)||--||This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.||Standard dates apply until January 8, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Pain Research Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Mission Areas||--||This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission.||This notice applies to subsequent receipt dates through January 10, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration||--||The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD).||This notice applies to subsequent receipt dates through May 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)||--||This seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries.||This notice applies to subsequent receipt dates through May 8, 2023.|
|NIH||NIH Notices of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems||--||The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered.|| Basic Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2023.
Population, Clinical and Applied Prevention Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2024.
|NIH||Notice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities||--||NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:|
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic||--||The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
|This notice applies to receipt dates through May 8, 2023.|
|NIH||Occupational Safety and Health Research (R01) ||--||The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.||Standard dates apply until November 18, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders||--||The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments.||This notice applies to subsequent receipt dates through December 7, 2023.|
|NIH||NIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes||--||This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:|
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
|This notice applies to receipt dates through January 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers||--||This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional) ||--||This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.||Standard AIDS dates apply until January 8, 2024.|
|NIH||NIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed) ||--||This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities.||Standard AIDS dates apply until January 8, 2024.|
|NIH||Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)||--||This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.||Standard dates apply until January 8, 2024.|
|NIH||Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders||--||National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.||This notice applies to receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition||-||This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.||This notice applies to subsequent receipt dates through January 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Telehealth in Cancer Care||--||This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.||This notice applies to subsequent receipt dates through March 8, 2024.|
|NIH||NIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes||--||National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.|
PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.
PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
|Standard dates apply until March 17, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies||--||National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.|
National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
|This notice applies to due dates on or after September 5, 2021 and subsequent receipt dates through May 7, 2024.|
|NIH||NIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)||--||This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.||Standard dates apply until May 8, 2024.|
|NIH||NIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)||--||This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data.||Standard dates apply until May 8, 2024.|
|NIH||Notice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis||--||This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.||This notice applies to receipt dates through May 8, 2024.|
|NIH||NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various Opportunities||Up to USD $50,000 per year for up to 2 years.|| PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. |
PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
|Standard dates apply until May 8, 2024.|
|NIH||NIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment||--||The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.|
PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional
|Standard dates apply until May 8, 2024.|
|NIH||NIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities||--||The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.|
PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
|Standard dates apply until May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide||--||This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.||This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities||--||This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.||This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research||--||This encourages grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.||This notice applies to due dates on or after March 7, 2022 and subsequent receipt dates through March 9, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health||--||This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.||This notice applies to subsequent receipt dates through June 8, 2024.|
|NIH||Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)||--||This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.||This notice applies to receipt dates through July 5, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning||--||This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.||This notice applies to subsequent receipt dates through September 7, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||--||National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.||This notice applies to due dates through September 7, 2024.|
|NIH||Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection||--||This NOSI encourages research to understand: |
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
|This notice applies to due dates through September 8, 2024.|
|NIH||NIH Basic Research in Cancer Health Disparities||--||This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.|
- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.
- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
|Standard dates apply until September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions||--||National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.||This notice applies to subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research||--||The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.||This notice applies to subsequent receipt dates through September 8, 2024.|
|NIH||NIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment||--||The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged.||This Notice applies to subsequent receipt dates through October 9, 2024.|
|NIH||NIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional)||--||This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trials||Standard dates apply until November 6, 2024.|
|NIH||NIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications||--||This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.|
- R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
-R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope.
|Standard dates apply until January 8, 2025.|
|NIH||NIH Drug Discovery for Nervous System Disorders||--||NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.|
R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
|Standard dates apply until January 8, 2025|
|NIH||NIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research||--||National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.||This Notice applies to due dates on or after February 15, 2022 and subsequent receipt dates through January 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Public Health Research on Cannabis||--||The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.||This notice applies to subsequent receipt dates through May 5, 2025.|
|NIH||NIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required)||--||This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.||Standard dates apply until May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction||--||The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection.||This notice applies to subsequent receipt dates through May 8, 2025.|
|NIH||NIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)||--||The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data.||Standard dates apply until May 8, 2025.|
|NIH||NIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)||--||This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention.||Standard dates apply until May 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment||--||This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).||This notice applies to subsequent receipt dates through September 8, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information||--||This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.||This notice applies to subsequent receipt dates through September 24, 2025.|
|NIH||NIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood||--||This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.||This notice applies to subsequent receipt dates through June 5, 2026.|
|NIH||NIH Parent Announcements||--||NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)|
Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)
Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)
NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
|Standard dates apply unless otherwise stated.|